Morgan Stanley Lowers Price Target for Organon & Co.

Organon & Co. (NYSE:OGN) has received a reassessment from Morgan Stanley, which has lowered its target price for the company from $17.00 to $16.00. This change came about in a research note published on Friday. Along with reducing the target price, Morgan Stanley has assigned an "equal weight" rating to the stock. The new price target implies a slight upside potential of about 0.45% compared to the company's current share price.

In another development, TD Cowen has upgraded Organon & Co. to a "hold" rating as of January 15. The overall ratings for the stock show mixed sentiments; one analyst has given a sell rating, three analysts have opted for a hold rating, one has recommended a buy, and another has given it a strong buy rating. The average analyst rating reflects a consensus of "Hold" with a target price averaging around $20.00, according to MarketBeat.com.

Current Stock Performance

During Friday's midday trading session, Organon & Co.'s shares saw a decline of 2.4%, trading down $0.39, which brought the stock price to $15.93. The trading volume for that day reached 306,014 shares, significantly lower than the average volume of 2,685,254 shares. Financial metrics for the company show a current ratio of 1.70 and a quick ratio of 1.21. Organon has a high debt-to-equity ratio of 17.73. The company's recent performance shows a 50-day moving average at $15.34, while the 200-day moving average stands at $17.53. Over the past year, the stock hit a lowest point of $13.87 and a peak of $23.10. Organon & Co. currently has a market capitalization valued at $4.10 billion, with a P/E ratio of 3.20 and a price-to-earnings-growth ratio of 0.83.

Recent Earnings Results

In terms of earnings, Organon & Co. released its latest quarterly results on February 13, where it reported earnings per share of $0.83. This result was below the market consensus estimate of $0.92 by $0.09. Notably, Organon has demonstrated a return on equity of an impressive 644.70% along with a net margin of 20.30%. Looking ahead, analysts predict that the company will achieve an EPS of 3.82 for the current fiscal year.

Institutional Involvement

Organon & Co. has seen various changes in its institutional ownership. For instance, Barclays PLC increased its stake in the company by 238% in the third quarter, bringing its total shares owned to 119,483. Wright Asset Management LP has also made a significant investment in Organon, acquiring shares valued at $32.9 million. Other firms, including Cerity Partners, Foundry Partners, and Beddow Capital, have also boosted their holdings in Organon during the same quarter. As it stands, institutional investors own approximately 77.43% of the company's total shares.

About Organon & Co.

Organon & Co. is a global pharmaceutical company focused on providing innovative health solutions. Founded on March 11, 2020, and headquartered in Jersey City, NJ, Organon primarily develops prescription therapies in areas such as women's health and biosimilars.

Organon, MorganStanley, Stock